Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on March 21 and set a price target of ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

Company announcement - No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand") (NA ...

Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 369,545,021.

No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.